[High-dose intravenous immunoglobulin treatment].

Hiromichi Taneichi*, Toshio Miyawaki

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Intravenous immunoglobulin treatment was introduced as replacement therapy for patients with congenital agammaglobulinemia. For the last three decades, high-dose intravenous immunoglobulin (HD-IVIg) has been used for autoimmune diseases and systemic inflammatory diseases, such as idiopathic thrombocytopenic purpura, Kawasaki disease, myasthenia gravis and Guillain-Barré/syndrome. Although the immunomodulatory mechanisms of HD-IVIg remains unclear. Its use in many other diseases have been expected. Acute encephalitis/encephalopathy is a complex neurological syndrome associated with significant morbidity and mortality. The pathogenicity of brain dysfunction is still unknown. This review provides an overview and discussion of mechanisms that may be responsible for HD-IVIg effects in acute encephalitis/encephalopathy.

Original languageEnglish
Pages (from-to)515-519
Number of pages5
JournalNihon rinsho. Japanese journal of clinical medicine
Volume69
Issue number3
StatePublished - 2011/03

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of '[High-dose intravenous immunoglobulin treatment].'. Together they form a unique fingerprint.

Cite this